
Leidos Hld (LDOS) Stock Forecast & Price Target
Leidos Hld (LDOS) Analyst Ratings
Bulls say
Leidos Holdings Inc. has demonstrated strong financial performance, particularly within its Health & Civil segment, where increased exam volumes have significantly driven margins. The company reported a notable 8% year-over-year growth in National Security revenues, reaching $2.02 billion, fueled by recent contract awards and growth in defense IT/mission support. Furthermore, the improvement in EBIT margins from 14.5% in 2023 to an anticipated 24.3% in the first half of 2025 underscores the company's operational efficiency and profitability trajectory.
Bears say
Leidos Holdings Inc. is experiencing a forecasted decline in margins, particularly anticipated in the second half of 2025 compared to the first half, raising concerns about long-term profitability. The company's higher-margin managed health services segment may also face further year-over-year declines due to increased competition, which presents a considerable risk to overall margins if medical exam volumes decrease significantly. Additionally, external factors such as protests against large contract wins, uncertainties in defense spending, potential government shutdowns, and regulatory risks tied to international operations further exacerbate the negative outlook on the stock.
This aggregate rating is based on analysts' research of Leidos Hld and is not a guaranteed prediction by Public.com or investment advice.
Leidos Hld (LDOS) Analyst Forecast & Price Prediction
Start investing in Leidos Hld (LDOS)
Order type
Buy in
Order amount
Est. shares
0 shares